Abstract: A device is provided for ultrasound-based reflection and transmission tomography. A plurality of ultrasonic transducers are held around an imaging volume to be filled with an ultrasonic coupling medium, the transducer holder having an opening for inserting, into the imaging volume, at least one part of a body to be imaged. During imaging, the body to be imaged is supported, where a support-member-opening allows access to the transducer holder by at least one part of the body. A diaphragm is arranged across the support-member-opening such that a center of a diaphragm-opening is placed substantially at a predetermined position. The ultrasonic coupling medium flows out of the imaging volume when at least one part of the body to be imaged is inserted into the imaging volume filled with the ultrasonic coupling medium and/or during imaging.

Abstract: A device (10) is provided for ultrasound-based reflection and transmission tomography.

Abstract: A device for ultrasound-assisted reflection and transmission tomography includes a measurement volume filled with an ultrasonic coupling medium and having an opening for inserting a body to be examined and a lateral surface remote from the opening, and a number of ultrasonic transducers arranged remotely from the opening of the measurement volume, arranged in direct contact with the ultrasonic coupling medium, and arranged oriented into the measurement volume. The arrangement of the ultrasonic transducers around the measurement volume aperiodically follows a random uniform distribution.

Abstract: A device for ultrasound-assisted reflection and transmission tomography includes a measurement volume filled with an ultrasonic coupling medium and having an opening for inserting a body to be examined and a lateral surface remote from the opening, and a number of ultrasonic transducers arranged remotely from the opening of the measurement volume, arranged in direct contact with the ultrasonic coupling medium, and arranged oriented into the measurement volume. The arrangement of the ultrasonic transducers around the measurement volume aperiodically follows a random uniform distribution.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.

Abstract: The present invention is directed to methods involving an AIB1 polypeptide. More particularly, the methods are directed to identifying an endocrine therapy-resistant patient, to providing a prognosis for disease-free survival of a cancer patient and to treating a cancer patient that is endocrine therapy-resistant.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.

Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.